BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Giuseppe Montalto, Céline Loncle, Audrey Benyamine, Véronique Secq, Anne-Sophie Chrétien, Céline Castanier, Elena Vila-Navarro, Juan-Luis Blazquez, Mauro Modesti, Etienne Foucher, Meritxell Gironella, Nelson Dusetti, Jean-Charles Dagorn, Salem Chouaib, Juan Iovanna, Daniel Olive

Risultato della ricerca: Article

7 Citazioni (Scopus)

Abstract

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC.
Lingua originaleEnglish
pagine (da-a)e1372080-
Numero di pagine14
RivistaOncoImmunology
Volume7
Stato di pubblicazionePublished - 2017

Fingerprint

Immunotherapy
Adenocarcinoma
T-Lymphocytes
Neoplasms
Protein Isoforms
Immunosuppressive Agents
Butyrophilins
Pancreatic Neoplasms
Heterografts
Cell Line
Food
Survival

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Cita questo

Montalto, G., Loncle, C., Benyamine, A., Secq, V., Chrétien, A-S., Castanier, C., ... Olive, D. (2017). BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). OncoImmunology, 7, e1372080-.

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). / Montalto, Giuseppe; Loncle, Céline; Benyamine, Audrey; Secq, Véronique; Chrétien, Anne-Sophie; Castanier, Céline; Vila-Navarro, Elena; Blazquez, Juan-Luis; Modesti, Mauro; Foucher, Etienne; Gironella, Meritxell; Dusetti, Nelson; Dagorn, Jean-Charles; Chouaib, Salem; Iovanna, Juan; Olive, Daniel.

In: OncoImmunology, Vol. 7, 2017, pag. e1372080-.

Risultato della ricerca: Article

Montalto, G, Loncle, C, Benyamine, A, Secq, V, Chrétien, A-S, Castanier, C, Vila-Navarro, E, Blazquez, J-L, Modesti, M, Foucher, E, Gironella, M, Dusetti, N, Dagorn, J-C, Chouaib, S, Iovanna, J & Olive, D 2017, 'BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)', OncoImmunology, vol. 7, pagg. e1372080-.
Montalto, Giuseppe ; Loncle, Céline ; Benyamine, Audrey ; Secq, Véronique ; Chrétien, Anne-Sophie ; Castanier, Céline ; Vila-Navarro, Elena ; Blazquez, Juan-Luis ; Modesti, Mauro ; Foucher, Etienne ; Gironella, Meritxell ; Dusetti, Nelson ; Dagorn, Jean-Charles ; Chouaib, Salem ; Iovanna, Juan ; Olive, Daniel. / BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). In: OncoImmunology. 2017 ; Vol. 7. pagg. e1372080-.
@article{6f8b09951fa44e6692f029fce83e7d98,
title = "BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)",
abstract = "Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC.",
author = "Giuseppe Montalto and C{\'e}line Loncle and Audrey Benyamine and V{\'e}ronique Secq and Anne-Sophie Chr{\'e}tien and C{\'e}line Castanier and Elena Vila-Navarro and Juan-Luis Blazquez and Mauro Modesti and Etienne Foucher and Meritxell Gironella and Nelson Dusetti and Jean-Charles Dagorn and Salem Chouaib and Juan Iovanna and Daniel Olive",
year = "2017",
language = "English",
volume = "7",
pages = "e1372080--",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

AU - Montalto, Giuseppe

AU - Loncle, Céline

AU - Benyamine, Audrey

AU - Secq, Véronique

AU - Chrétien, Anne-Sophie

AU - Castanier, Céline

AU - Vila-Navarro, Elena

AU - Blazquez, Juan-Luis

AU - Modesti, Mauro

AU - Foucher, Etienne

AU - Gironella, Meritxell

AU - Dusetti, Nelson

AU - Dagorn, Jean-Charles

AU - Chouaib, Salem

AU - Iovanna, Juan

AU - Olive, Daniel

PY - 2017

Y1 - 2017

N2 - Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC.

AB - Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC.

UR - http://hdl.handle.net/10447/299166

UR - http://www.tandfonline.com/loi/koni20

M3 - Article

VL - 7

SP - e1372080-

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

ER -